PubMed Health⌕ Search

PubMed · 10945148

[News from UKPDS].

Abstract

Risk factors present in type 2 diabetic patients at the time of their inclusion in the study were related with the occurrence of some complications. Thus, relative risk for coronary heart disease is 1.57 when HbA1c is > 7.5%, 1.41 when LDL-Cholesterol is > 3.89 mmol/l, these factors are not involved in the occurrence of cerebral stroke. Blood pressure and HbA1c were monitored throughout the study and could have been significantly correlated with the occurrence of micro- and macroangiopathy, with a linear-type and even exponential (HbA1c/retinopathy) relationship and a synergistic interaction between these 2 parameters. A treatment allowing a 0.9% decrease of HbA1c and a 10 mmHg decrease of systolic blood pressure is associated with a reduction of complications, more or less important than that expected from the epidemiological analysis of data. Several therapeutic strategies ensue from these observations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Andreelli. 2000. [News from UKPDS].. https://pubmed.ncbi.nlm.nih.gov/10945148/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Molecular biology of PCSK9: its role in LDL metabolism.

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Cholesterol, LDL↗

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Statins are normally administered for the treatment of dyslipidemia on a daily basis. This standard dosing regimen is well tolerated by most patients. Occasionally, patients discontinue therapy secondary to side effects, most commonly myalgias. We describe 2 patients who were unable to tolerate daily atorvastatin therapy secondary to myalgias and were subsequently treated with rosuvastatin administered on Mondays, Wednesdays, and Fridays, with resolution of adverse effects. Significant reductions in serum low-density lipoprotein cholesterol levels were observed in the 2 patients despite the alternate-day dosing regimen. Rosuvastatin was chosen because of its long half-life (19 hours) and very high potency.

Cholesterol, LDL↗